VANCOUVER, Sept. 18 /PRNewswire-FirstCall/ - AnorMED Inc. (NASDAQ:ANOR - News; TSX:AOM - News) today announced that under the terms of an existing agreement, AnorMED will receive a U.S.$3 million milestone payment from Shire Pharmaceuticals Group, plc based on the recent licensing approval received in Germany by Shire to sell FOSRENOL as a treatment for high phosphate levels in the blood, which occurs in patients undergoing dialysis as a result of chronic kidney failure.
